Age Related Macular Degeneration (AMD) is a worldwide public health challenge. It is by far the most common cause of sight loss in the developed world.
In spite of many advances in genetics, pathogenesis and epidemiology we do not know how to prevent the disease from progressing from the benign early stages to the advanced end stages involving debilitating sight losses in all cases.
A mild but progressive loss of sight, distortion of straight lines, loss of night vision depending on severity.
Early AMD accounts for around 80% of the total number of patients.
Patients with wet AMD are severely disabled (see figure 1). They become a major burden on health care systems. Symptoms include: